{"id":"talc-slurry-pleurodesis","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Chest pain"},{"rate":"10-30","effect":"Fever"},{"rate":"10-20","effect":"Dyspnea"},{"rate":"0.5-2","effect":"Acute respiratory distress syndrome (ARDS)"},{"rate":"1-5","effect":"Empyema"},{"rate":"5-15","effect":"Hypoxemia"}]},"_chembl":{"chemblId":"CHEMBL3989756","moleculeType":"Small molecule","molecularWeight":"379.26"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"When instilled into the pleural cavity, talc particles trigger an inflammatory response that leads to adhesion and fusion of the visceral and parietal pleura. This obliteration of the pleural space prevents the reaccumulation of pleural effusion, providing long-term control of recurrent malignant or benign pleural effusions. The mechanism is primarily physical and inflammatory rather than pharmacological.","oneSentence":"Talc slurry induces chemical pleurodesis by causing inflammation and fibrosis of the pleural surfaces, obliterating the pleural space to prevent fluid reaccumulation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:56.795Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Recurrent malignant pleural effusion"},{"name":"Recurrent benign pleural effusion (pneumothorax, heart failure)"}]},"trialDetails":[{"nctId":"NCT07167992","phase":"NA","title":"Comparison of Talc Slurry Versus Talc Insufflation: A Study on Effectiveness, Safety, and Hospital Outcomes in Pleurodesis","status":"NOT_YET_RECRUITING","sponsor":"University of Health Sciences Lahore","startDate":"2026-02-01","conditions":"Pneumothorax Spontaneous Primary, Pneumothorax Spontaneous Secondary, Pleural Effusion, Malignant","enrollment":160},{"nctId":"NCT04806373","phase":"PHASE4","title":"Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis","status":"COMPLETED","sponsor":"Memorial Healthcare System","startDate":"2021-06-15","conditions":"Pleural Effusion","enrollment":27},{"nctId":"NCT06883188","phase":"PHASE2, PHASE3","title":"Stop Air Leak by Talc or Autologous Blood Patch Therapy","status":"NOT_YET_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2026-04-01","conditions":"Pneumothorax Spontaneous Secondary","enrollment":30},{"nctId":"NCT02517749","phase":"NA","title":"Out Patient Talc Slurry Via Indwelling Pleural Catheter for Malignant Pleural Effusion Vs Usual Inpatient Management","status":"COMPLETED","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2015-08","conditions":"Pleural Effusion, Malignant","enrollment":142},{"nctId":"NCT04130451","phase":"PHASE1, PHASE2","title":"Efficacy, Safety and Re-occurrence of Pneumothorax and Hydro-pneumothorax With Talc and Pyodine Pleurodesis","status":"UNKNOWN","sponsor":"Dow University of Health Sciences","startDate":"2019-10-25","conditions":"Secondary Pneumothorax","enrollment":104},{"nctId":"NCT03973957","phase":"NA","title":"Talc Outpatient Pleurodesis With Indwelling Catheter","status":"UNKNOWN","sponsor":"The Cooper Health System","startDate":"2019-05-27","conditions":"Pleural Effusion, Pleural Diseases, Malignant Pleural Effusion","enrollment":124},{"nctId":"NCT01973985","phase":"","title":"Using Ultrasound to Predict the Results of Draining Pleural Effusions","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2014-08-01","conditions":"Pleural Effusion","enrollment":2},{"nctId":"NCT03319186","phase":"NA","title":"EDIT Management Feasibility Trial","status":"UNKNOWN","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2017-08-28","conditions":"Pleural Effusion, Malignant","enrollment":30},{"nctId":"NCT00042770","phase":"PHASE3","title":"Standard Chest Tube Compared With a Small Catheter in Treating Malignant Pleural Effusion in Patients With Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2002-05","conditions":"Metastatic Cancer, Pulmonary Complications","enrollment":67},{"nctId":"NCT01409551","phase":"NA","title":"Video-assisted Hyperthermic Pleural Chemoperfusion vs Talc Pleurodesis for Refractory Malignant Pleural Effusions.","status":"COMPLETED","sponsor":"Theagenio Cancer Hospital","startDate":"2011-08","conditions":"Safety of Intervention, Efficacy of Intervention, Cost Effectiveness","enrollment":60},{"nctId":"NCT02045121","phase":"NA","title":"Multicentre Study Comparing Indwelling Pleural Catheter With Talc Pleurodesis for Malignant Pleural Effusion Management","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2014-01","conditions":"Pleural Effusion, Malignant","enrollment":160},{"nctId":"NCT00789087","phase":"PHASE4","title":"Talc Pleurodesis in Patients With Recurrent Malignant Pleural Effusion","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2005-01","conditions":"Recurrent Malignant Pleural Effusion.","enrollment":60},{"nctId":"NCT00430664","phase":"NA","title":"A Comparative Study of the Safety and Efficacy of Face Talc Slurry and Iodopovidone for Pleurodesis","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2006-01","conditions":"Malignant Pleural Effusions, Recurrent Pleural Effusions, Primary Spontaneous Pneumothorax","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TSP"],"phase":"marketed","status":"active","brandName":"Talc Slurry Pleurodesis","genericName":"Talc Slurry Pleurodesis","companyName":"Memorial Healthcare System","companyId":"memorial-healthcare-system","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Talc slurry induces chemical pleurodesis by causing inflammation and fibrosis of the pleural surfaces, obliterating the pleural space to prevent fluid reaccumulation. Used for Recurrent malignant pleural effusion, Recurrent benign pleural effusion (pneumothorax, heart failure).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}